New England Journal of Medicine December 16, 2021

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Kevin Kalinsky, William E. Barlow, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, et al.

Bottom Line

In women with hormone-receptor-positive, HER2-negative breast cancer with 1 to 3 positive lymph nodes and a 21-gene recurrence score of 25 or lower, postmenopausal women derive no benefit from adjuvant chemotherapy, whereas premenopausal women experience significantly improved invasive disease-free survival.

Key Findings

1. A total of 5,083 women were randomized into the trial, consisting of 33.2% premenopausal and 66.8% postmenopausal participants.

2. The benefit of adjuvant chemotherapy for increasing invasive disease-free survival differed significantly according to menopausal status (P = 0.008 for the interaction).

3. Among postmenopausal women, 5-year invasive disease-free survival was 91.9% in the endocrine-only group and 91.3% in the chemoendocrine group, demonstrating no chemotherapy benefit (HR 1.02; 95% CI, 0.82 to 1.26; P = 0.89).

4. Among premenopausal women, 5-year invasive disease-free survival was significantly improved with chemoendocrine therapy (93.9%) compared to endocrine-only therapy (89.0%), yielding a hazard ratio of 0.60 (95% CI, 0.43 to 0.83; P = 0.002).

5. Premenopausal women also experienced a significant increase in distant relapse-free survival with the addition of chemotherapy (HR 0.58; 95% CI, 0.39 to 0.87; P = 0.009).

6. The relative benefit of chemotherapy did not increase as the recurrence score increased.

Study Design

Design

Randomized Controlled Trial

Open-Label

Sample

5,083

Patients

Duration

5 yr

Median

Setting

International multicenter

Population Women with hormone-receptor-positive, HER2-negative breast cancer, 1 to 3 positive axillary lymph nodes, and a 21-gene recurrence score of 25 or lower.

Intervention Adjuvant chemotherapy followed by endocrine therapy (chemoendocrine therapy).

Comparator Adjuvant endocrine therapy only.

Outcome Invasive disease-free survival (IDFS).

Study Limitations

• It remains unresolved whether the benefit observed in premenopausal women is a direct cytotoxic effect of chemotherapy or an indirect effect mediated by chemotherapy-induced ovarian function suppression, especially given the low rates of ovarian function suppression utilized in the endocrine-alone arm of the trial.

• The trial did not prospectively collect serial serum samples to longitudinally assess ovarian reserve after treatment, and gynecologic comorbidities that could impact biomarker levels (e.g., polycystic ovary syndrome) were not reliably captured.

• The reported outcome timeframe focuses on 5-year survival metrics, which provides relatively short follow-up for hormone-receptor-positive breast cancer given its well-documented risk of late recurrences persisting over decades.

Clinical Significance

The RxPONDER trial established a new global standard of care by demonstrating that routine adjuvant chemotherapy can be safely omitted in postmenopausal women with HR-positive, HER2-negative breast cancer who have 1 to 3 positive nodes and a recurrence score of 0 to 25. Conversely, it affirmed the utility of chemotherapy in premenopausal women with identical clinical and genomic characteristics, though it sparked ongoing debate regarding whether optimal ovarian function suppression might one day replace chemotherapy in this younger demographic.

Historical Context

Historically, the presence of positive axillary lymph nodes strongly mandated adjuvant chemotherapy in early-stage breast cancer due to an elevated risk of recurrence. While the development of the 21-gene recurrence score (Oncotype DX) and the landmark TAILORx trial successfully de-escalated chemotherapy use in node-negative disease, uncertainty remained for node-positive patients. Retrospective analyses of node-positive cohorts (such as the SWOG S8814 trial) hypothesized that postmenopausal women with low recurrence scores might also safely forgo chemotherapy. The RxPONDER trial (SWOG S1007) was uniquely designed to definitively and prospectively answer this question, representing a major milestone in precision oncology by effectively sparing thousands of postmenopausal women the toxicities of chemotherapy each year.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the physiological mechanism of ovarian suppression induced by chemotherapy explain the differing benefits seen between premenopausal and postmenopausal women in this study?

Key Response

Chemotherapy in premenopausal women often induces premature ovarian failure, effectively acting as profound endocrine therapy by removing the primary source of estrogen. Postmenopausal women already lack ovarian estrogen production, which may explain why chemotherapy offers no additional endocrine-mediated benefit in this specific tumor biology, highlighting the interplay between cytotoxic and endocrine effects.

Resident

A 55-year-old postmenopausal woman with HR-positive, HER2-negative breast cancer and 2 positive axillary lymph nodes has an Oncotype DX score of 18. Based on the RxPONDER trial, how should you counsel her regarding adjuvant chemotherapy, and how does this differ from historical management?

Key Response

Historically, any node-positive breast cancer was considered an automatic indication for adjuvant chemotherapy. Based on RxPONDER, this patient (postmenopausal, 1-3 positive nodes, Recurrence Score 25 or less) can be safely advised that chemotherapy will not improve her invasive disease-free survival, allowing her to avoid chemotherapy toxicity and proceed directly to endocrine therapy.

Fellow

Given the significant invasive disease-free survival benefit of chemotherapy in premenopausal women with a recurrence score of 25 or lower, how do we differentiate whether this benefit is truly from chemotherapy's cytotoxic effects versus secondary ovarian suppression, and how might the use of ovarian function suppression (OFS) plus an aromatase inhibitor alter this paradigm?

Key Response

A major debate in breast oncology is whether the chemotherapy benefit in premenopausal women with low to intermediate recurrence scores is purely an indirect endocrine effect (chemo-induced amenorrhea). If so, optimizing endocrine therapy with GnRH agonists (OFS) plus aromatase inhibitors (as seen in the SOFT/TEXT trials) might replace the need for chemotherapy in this cohort, a hypothesis currently being tested in trials like OFSET.

Attending

For a 45-year-old premenopausal patient with 2 positive nodes and a recurrence score of 12, how do you navigate the shared decision-making process when discussing chemotherapy, considering the absolute benefit observed in RxPONDER versus the long-term toxicities, and the unresolved question of optimal endocrine therapy substitution?

Key Response

Navigating this scenario requires nuanced communication. The absolute IDFS benefit at 5 years in premenopausal women was roughly 5%, which is clinically meaningful but must be weighed against risks of leukemia, neuropathy, and premature menopause. The attending must balance Level 1 evidence of chemotherapy benefit against the biological rationale that maximizing endocrine therapy (OFS plus AI) might achieve the same outcome without cytotoxic risks, tailoring the choice to patient values.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The trial evaluated the primary endpoint but found a significant interaction between menopausal status and chemotherapy benefit. Statistically, how does an unexpected, strong interaction effect in a subgroup complicate the interpretation of a trial's primary overall endpoint, and what statistical safeguards were necessary to validate the premenopausal findings?

Key Response

When a trial's primary overall analysis is confounded by a massive qualitative interaction (where one subgroup derives zero benefit and another derives significant benefit), the overall hazard ratio becomes heavily diluted and potentially misleading. A researcher must evaluate the pre-planned nature of the subgroup analysis, the powering of the interaction test (p=0.004 here), and the alpha-spending rules used to ensure the premenopausal finding is a robust conclusion rather than a spurious subgroup artifact.

Journal Editor

A critical peer reviewer might flag the adherence and type of endocrine therapy used in the control arms as a major confounder. How does the variability in the utilization of ovarian function suppression (only 16% in the premenopausal control arm) threaten the internal validity of the conclusion that chemotherapy is intrinsically necessary for this cohort?

Key Response

If the control arm (endocrine therapy alone) received suboptimal endocrine therapy (e.g., tamoxifen alone without ovarian suppression) compared to the de facto ovarian suppression achieved in the chemotherapy arm, the trial may be unfairly penalizing the endocrine-only arm. An editor must scrutinize whether this imbalance artificially inflated the apparent efficacy of chemotherapy in premenopausal women.

Guideline Committee

In light of the RxPONDER data, how should ASCO and NCCN guidelines formally update their recommendations regarding genomic testing and chemotherapy for HR-positive, HER2-negative breast cancer with 1 to 3 positive nodes, and what Level of Evidence should be assigned to the omission of chemotherapy in the postmenopausal subgroup?

Key Response

The findings provide Level 1 evidence to strongly recommend (Category 1 in NCCN) using the 21-gene recurrence score in postmenopausal women with 1 to 3 positive nodes, as a score of 25 or less definitively supports omitting chemotherapy. The guidelines must now explicitly stratify treatment algorithms by menopausal status for limited node-positive disease, moving away from a purely node-driven chemotherapy mandate that dominated prior iterations of clinical guidelines.

Clinical Landscape

Noteworthy Related Trials

2010

SWOG S8814 Trial

n = 367 · Lancet Oncol

Tested

21-gene recurrence score assessment

Population

Postmenopausal women with node-positive, HR+ breast cancer

Comparator

CAF plus tamoxifen vs tamoxifen alone

Endpoint

Disease-free survival

Key result: The 21-gene recurrence score was highly predictive of chemotherapy benefit in node-positive disease, with high-score patients benefiting significantly while low-score patients did not.

2016

MINDACT Trial

n = 6,693 · NEJM

Tested

Treatment decisions based on 70-gene signature (MammaPrint)

Population

Women with early-stage breast cancer (node-negative or 1-3 positive nodes) at high clinical risk but low genomic risk

Comparator

Treatment decisions based on standard clinical-pathological criteria

Endpoint

5-year survival without distant metastasis

Key result: Patients with high clinical risk but low genomic risk who omitted chemotherapy had a 5-year survival without distant metastasis of 94.7%.

2018

TAILORx Trial

n = 10,273 · NEJM

Tested

Endocrine therapy alone

Population

Women with HR+, HER2-, node-negative breast cancer and midrange 21-gene recurrence score (11-25)

Comparator

Chemoendocrine therapy

Endpoint

Invasive disease-free survival

Key result: Endocrine therapy was noninferior to chemoendocrine therapy in patients with a midrange recurrence score, though some benefit was seen in women 50 years or younger.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis